-+ 0.00%
-+ 0.00%
-+ 0.00%
Tarsus Pharmaceuticals (TARS) Earnings Put Its Valuation Narrative Back In Focus
Share
Listen to the news

Tarsus Pharmaceuticals (TARS) has just released third quarter 2026 results that combined higher revenue with a much larger loss, a mix that often makes investors reassess risk and expectations.

The earnings release on 3 November appears to be the main catalyst behind the recent jump in Tarsus Pharmaceuticals, with the stock logging a 17.03% 7 day share price return and a 16.01% 90 day share price return. The 3 year total shareholder return of roughly 3x signals longer term momentum that contrasts with a slightly negative year to date share price move.

Compare Tarsus Pharmaceuticals with a curated group of eye care and biotech peers showing strong fundamentals and balance sheets through our list of solid balance sheet and fundamentals (24 results).

Tarsus Pharmaceuticals just posted surging revenue alongside a far larger loss, and the share price has already reacted. Does that recent rerating still leave enough upside in the risk reward to interest new buyers?

Most Popular Narrative: 21.7% Undervalued

Tarsus Pharmaceuticals closed at $80.28, while the analyst consensus Narrative on Simply Wall St points to a fair value of $102.56. This frames the stock as materially undervalued and puts the focus on whether its eye care portfolio can support that gap over time.

Accelerated patient and physician adoption of XDEMVY, supported by more than 1 million bottles dispensed, over US$1b in cumulative net sales and a growing retreatment share around the low 20% range, points to continued expansion of the Demodex blepharitis category and a potential lift to ongoing revenue and contribution margin.

See why 15 investors see Tarsus Pharmaceuticals as 22% undervalued.

Result: Fair Value of $102.56 (UNDERVALUED)

Still, the rising SG&A and direct to consumer spend, along with the short seller claims around XDEMVY’s Medicare copay support, could quickly challenge the Tarsus Pharmaceuticals bull case.

Find out about the key risks to this Tarsus Pharmaceuticals narrative.

Next Steps

Mixed signals around Tarsus Pharmaceuticals can be useful if viewed early and with a clear head. Dig into the data while it is still fresh and pressure test both the bullish and cautious arguments by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Tarsus Pharmaceuticals?

Do not stop with Tarsus Pharmaceuticals. Broaden your watchlist with fresh setups that match your risk, income, and value preferences using the Simply Wall St screener.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending